LIFECORE BIOMEDICAL, INC. Cash and Restricted Cash
LIFECORE BIOMEDICAL, INC. (LFCR) had Cash and Restricted Cash of $17.24 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $17.24M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $20.80M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $17.47M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $18.86M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $17.24M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $20.80M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $17.47M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $18.86M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $20.22M 10-Q · filed 2025-11-06 | |
| 2025-05-25 | $8.27M 10-Q · filed 2026-08-05 | |
| 2025-02-23 | $5.42M 10-Q · filed 2026-05-06 | $5.42M 10-Q · filed 2025-04-03 |
| 2024-11-24 | $9.46M 10-Q · filed 2026-08-05 | |
| 2024-08-25 | $5.52M 10-Q · filed 2025-11-06 | |
| 2024-05-26 | $8.46M 10-KT · filed 2026-03-16 | |
| 2024-02-25 | $3.07M 10-Q · filed 2025-04-03 | |
| 2023-11-26 | $3.22M 10-Q · filed 2025-01-02 | |
| 2023-08-27 | $8.64M 10-Q · filed 2024-10-04 | |
| 2023-05-28 | $19.09M 10-KT · filed 2026-03-16 | |
| 2023-02-26 | $2.95M 10-Q · filed 2024-08-09 | |
| 2022-11-27 | $6.83M 10-Q · filed 2024-08-09 | |
| 2022-08-28 | $4.22M 10-Q · filed 2024-08-09 | |
| 2022-05-29 | $1.64M 10-K · filed 2024-08-26 | |
| 2022-02-27 | $1.85M 10-K · filed 2024-03-20 | |
| 2021-11-28 | $1.09M 10-K · filed 2024-03-20 | |
| 2021-08-29 | $1.45M 10-K · filed 2024-03-20 | |
| 2021-05-30 | $1.29M 10-K · filed 2024-08-26 | |
| 2021-02-28 | $2.25M 10-K · filed 2024-03-20 | |
| 2020-11-29 | $2.49M 10-Q · filed 2022-01-07 | |
| 2020-08-30 | $589.00K 10-K · filed 2024-03-20 | $782.00K 10-Q · filed 2020-10-07 |
| 2020-05-31 | $553.00K 10-K · filed 2024-03-20 | |
| 2020-02-23 | $2.80M 10-Q · filed 2021-04-08 | |
| 2019-11-24 | $1.98M 10-Q · filed 2021-01-07 | |
| 2019-08-25 | $2.38M 10-Q · filed 2020-10-07 | |
| 2019-05-26 | $1.47M 10-K/A · filed 2023-03-16 | |
| 2018-05-27 | $3.22M 10-K · filed 2021-07-29 | |
| 2017-05-28 | $5.73M 10-K · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |